Filtered Decision Variables – Guideline Analytics

This filter utilizes the SimMetrics CosineSimilarity class to identify an optimum match of Decision Variable and UMLS CUI.
Guideline Title	Conditional	DocumentID	Decision Variable	UMLS Code	Code Text
Heart Failure 2017 ACC/AHA/HFSA	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	32475	Serial monitoring indicated	C3526969	extended monitoring
Heart Failure 2017 ACC/AHA/HFSA	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	32475	Serial monitoring indicated	C0015945	Fetal Monitoring
Heart Failure 2017 ACC/AHA/HFSA	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	32477	selected patients who present with HF	C1144864	Family/couple with client present
Heart Failure 2017 ACC/AHA/HFSA	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	32480	patients presenting with dyspnea	C2368562	Dyspnea screened dyspnea mild dyspnea (Pall
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	32487	patients with HF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	32487	patients with HF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	32488	no angina	C3248525	Angina absent (CAD)
Heart Failure 2017 ACC/AHA/HFSA	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	32488	no angina	C3248257	Angina present (CAD)
Heart Failure 2017 ACC/AHA/HFSA	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	32490	echocardiography is inadequate	C0013516	Echocardiography
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	32500	obesity	C3511720	Anesthesia procedure stomach obesity including endoscope
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	32500	diabetes mellitus	C3534868	Screening tests diabetes mellitus reviewed requested ordered (DSP)
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	32500	diabetes mellitus	C4523705	Diabetes Prevention Programs
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	32500	tobacco use	C1314131	Tobacco assessed
Heart Failure 2017 ACC/AHA/HFSA	Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided.	32500	tobacco use	C2724381	Patient screened tobacco received tobacco cessation intervention (counseling pharmacotherapy both) identified tobacco user (PV CAD)
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	32501	acute coronary syndrome	C0810126	coronary thrombolysis
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	32501	reduced EF	C0520252	Reduced Services
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	32502	acute coronary syndrome	C0810126	coronary thrombolysis
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated.	32502	reduced EF	C0520252	Reduced Services
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	32503	acute coronary syndrome	C0810126	coronary thrombolysis
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality.	32503	reduced EF	C0520252	Reduced Services
Heart Failure 2017 ACC/AHA/HFSA	In all patients with a recent or remote history of MI or acute coronary syndrome, statins should be used to prevent symptomatic Heart Failure and cardiovascular events.	32504	acute coronary syndrome	C0810126	coronary thrombolysis
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	32508	are on appropriate medical therapy	C0918259	medical nutritional therapy
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	32508	are on appropriate medical therapy	C1257928	Medical Nutrition Therapy
Heart Failure 2017 ACC/AHA/HFSA	To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year.	32508	are on appropriate medical therapy	C3527118	Group medical nutrition therapy
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure should receive specific education to facilitate Heart Failure self-care.	32510	Patients with HF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure should receive specific education to facilitate Heart Failure self-care.	32510	Patients with HF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Exercise training (or regular physical activity) is recommended as safe and effective for patients with Heart Failure who are able to participate to improve functional status.	32512	patients with HF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Exercise training (or regular physical activity) is recommended as safe and effective for patients with Heart Failure who are able to participate to improve functional status.	32512	patients with HF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	Stage C patient with HFrEF	C0973439	patient with mild systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	Stage C patient with HFrEF	C3526570	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	Stage C patient with HFrEF	C2065027	Family psychotherapy with patient present
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	Stage C patient with HFrEF	C3526576	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	Stage C patient with HFrEF	C0973444	patient with severe systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	Stage C patient with HFrEF	C3526564	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	NYHA class I-IV	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	NYHA class I-IV	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I)	32516	NYHA class I-IV	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, provided est. CrCl >30 mL/min & K+ <5.0 mEq/L implement Aldosterone antagonist (COR I)	32517	patient is NYHA class II–IV	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III Heart Failure Adequate BP on ACEI or ARB; No C/I to ARB or sacubitril then Discontinue ACEI or ARB; initiate ARNI	32518	NYHA class II–III HF	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	32519	NYHA class III–IV	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	32519	NYHA class III–IV	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	32519	NYHA class III–IV	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class III?IV, in black patients implment Hydral-Nitrates	32519	in black patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	NYHA class II–III	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	NYHA class II–III	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	NYHA class II–III	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	left ventricular ejection fraction ?35%	C3520484	Repositioning left ventricular electrode
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	left ventricular ejection fraction ?35%	C1736907	Left ventricular ejection fraction (LVEF) less than documentation moderately severely depressed left ventricular systolic function (CAD
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	left ventricular ejection fraction ?35%	C1736638	Left ventricular ejection fraction (LVEF) greater than equal documentation normal mildly depressed left ventricular systolic function (CAD
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	left ventricular ejection fraction ?35%	C3248278	Left ventricular ejection fraction (LVEF) greater than LVEF result available (HF)
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	left ventricular ejection fraction ?35%	C3248277	Left ventricular ejection fraction (LVEF) less than equal (HF)
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator	32520	left ventricular ejection fraction ?35%	C3248276	Left ventricular ejection fraction (LVEF) assessment planned post discharge (HF)
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	NYHA class II–IV	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	NYHA class II–IV	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	NYHA class II–IV	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	left ventricular ejection fraction ?35%	C3520484	Repositioning left ventricular electrode
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	left ventricular ejection fraction ?35%	C1736907	Left ventricular ejection fraction (LVEF) less than documentation moderately severely depressed left ventricular systolic function (CAD
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	left ventricular ejection fraction ?35%	C1736638	Left ventricular ejection fraction (LVEF) greater than equal documentation normal mildly depressed left ventricular systolic function (CAD
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	left ventricular ejection fraction ?35%	C3248278	Left ventricular ejection fraction (LVEF) greater than LVEF result available (HF)
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	left ventricular ejection fraction ?35%	C3248277	Left ventricular ejection fraction (LVEF) less than equal (HF)
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?IV, LVEF ?35%, NSR & QRS ?150 ms with LBBB pattern	32521	left ventricular ejection fraction ?35%	C3248276	Left ventricular ejection fraction (LVEF) assessment planned post discharge (HF)
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	32522	NYHA class II–III,	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	32522	NYHA class II–III,	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	NYHA class II?III, NSR, heart rate ?70 bpm on maximally tolerated dose beta blocker	32522	NYHA class II–III,	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF with fluid retention	32524	patients with HFrEF with fluid retention	C0523406	Immunoelectrophoresis body fluid with concentration
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors are recommended for all patients with Heart FailurerEF	32525	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	ACE inhibitors are recommended for all patients with Heart FailurerEF	32525	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF who are ACE inhibitor–intolerant	32526	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	ARBs are recommended in patients with Heart FailurerEF who are ACE inhibitor–intolerant	32526	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C0973439	patient with mild systemic disease
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C3526570	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C2065027	Family psychotherapy with patient present
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C1113679	patient safety
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C3526576	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C0497702	Aphakic patient
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C0973444	patient with severe systemic disease
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C3526564	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	patient with HFrEF	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C3514891	Insertion radiation therapy devices uterus radiation therapy
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C3514892	Insertion radiation therapy devices vagina radiation therapy
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C1444296	Occupational therapy assessment
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C1444299	Physical therapy assessment
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C0198856	Anesthesia electroconvulsive therapy
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C0150318	Radiation therapy management
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C0918259	medical nutritional therapy
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C1257928	Medical Nutrition Therapy
Heart Failure 2017 ACC/AHA/HFSA	ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in Heart FailurerEF	32527	first-line therapy	C0886115	Administration radiation therapy
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	32529	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	32529	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	32530	stable patients	C1314211	Three patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	32530	stable patients	C1314212	Four patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	32530	stable patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	32530	stable patients	C1314213	Five patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients	32530	stable patients	C1314214	more patients served
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful in patients with Heart FailurerEF who cannot be given ACE inhibitors or ARBs	32535	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	A combination of hydralazine and isosorbide dinitrate can be useful in patients with Heart FailurerEF who cannot be given ACE inhibitors or ARBs	32535	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	32536	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	32536	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	32540	patients with chronic HFrEF without AF	C0373216	Urography (pyelography) intravenous with without KUB with without tomography
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	32540	patients with chronic HFrEF without AF	C3701851	Conization cervix with without fulguration with without dilation curettage with without repair
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source	32540	patients with chronic HFrEF without AF	C0373220	Urography retrograde with without
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFrEF patients	C1314211	Three patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFrEF patients	C1314212	Four patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFrEF patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFrEF patients	C1314213	Five patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFrEF patients	C1314214	more patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFpEF patients	C1314211	Three patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFpEF patients	C1314212	Four patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFpEF patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFpEF patients	C1314213	Five patients served
Heart Failure 2017 ACC/AHA/HFSA	Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in Heart FailurerEF or Heart FailurepEF patients	32542	HFpEF patients	C1314214	more patients served
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C0973439	patient with mild systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C3526570	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C2065027	Family psychotherapy with patient present
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C1113679	patient safety
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C3526576	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C0497702	Aphakic patient
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C0973444	patient with severe systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C3526564	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Hormonal therapies other than to correct deficiencies are NOT recommended in Heart FailurerEF	32544	patient with HFrEF	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment	32546	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment	32546	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C0973439	patient with mild systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C3526570	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C2065027	Family psychotherapy with patient present
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C1113679	patient safety
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C3526576	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C0497702	Aphakic patient
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C0973444	patient with severe systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C3526564	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment in Heart FailurerEF	32547	patient with HFrEF	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor.	32553	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor.	32553	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Angiotensin receptor-neprilysin inhibitor should not be administered to patients with a history of angioedema.	32554	patients with a history of angioedema	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF who have evidence of fluid retention, unless contraindicated, to improve symptoms.	32556	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Diuretics are recommended in patients with Heart FailurerEF who have evidence of fluid retention, unless contraindicated, to improve symptoms.	32556	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	32561	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful for patients with Heart FailurerEF.	32561	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency.	32563	patients with NYHA class II–IV	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	32565	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	32565	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	32565	potassium >5.0 mEq/L	C0202194	Potassium measurement
Heart Failure 2017 ACC/AHA/HFSA	Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency when serum creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women (or estimated glomerular filtration rate <30 mL/min/1.73 m2), and/or potassium >5.0 mEq/L.	32565	potassium >5.0 mEq/L	C0858155	Plasma potassium
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	32568	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Digoxin can be beneficial in patients with Heart FailurerEF, unless contraindicated, to decrease hospitalizations for Heart Failure.	32568	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C3534860	Patient dysarthric (ALS)
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C0973438	normal healthy patient
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C1113679	patient safety
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C0497702	Aphakic patient
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C3534859	Patient dysarthric (ALS)
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C0519731	Patient Home Services
Heart Failure 2017 ACC/AHA/HFSA	The selection of an anticoagulant agent (warfarin, dabigatran, apixaban, or rivaroxaban) for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin.	32570	patient preference	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	32572	patients with chronic HFrEF without AF	C0373216	Urography (pyelography) intravenous with without KUB with without tomography
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	32572	patients with chronic HFrEF without AF	C3701851	Conization cervix with without fulguration with without dilation curettage with without repair
Heart Failure 2017 ACC/AHA/HFSA	Anticoagulation is NOT recommended in patients with chronic Heart FailurerEF without AF, a prior thromboembolic event, or a cardioembolic source. (III-B: No Benefit)	32572	patients with chronic HFrEF without AF	C0373220	Urography retrograde with without
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment (see recommendations for stage D starting on page 34).	32578	patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of infused positive inotropic drugs is potentially harmful for patients with Heart FailurerEF, except as palliation for patients with end-stage disease who cannot be stabilized with standard medical treatment (see recommendations for stage D starting on page 34).	32578	patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment for patients with Heart FailurerEF.	32579	patients with HFrEF.	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Calcium channel–blocking drugs are NOT recommended as routine treatment for patients with Heart FailurerEF.	32579	patients with HFrEF.	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Systolic and diastolic blood pressure should be controlled in patients with Heart FailurepEF in accordance with published clinical practice guidelines to prevent morbidity.	32580	patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Systolic and diastolic blood pressure should be controlled in patients with Heart FailurepEF in accordance with published clinical practice guidelines to prevent morbidity.	32580	patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Diuretics should be used for relief of symptoms due to volume overload in patients with Heart FailurepEF.	32581	patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Diuretics should be used for relief of symptoms due to volume overload in patients with Heart FailurepEF.	32581	patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Management of AF according to published clinical practice guidelines in patients with Heart FailurepEF is reasonable to improve symptomatic Heart Failure.	32583	patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Management of AF according to published clinical practice guidelines in patients with Heart FailurepEF is reasonable to improve symptomatic Heart Failure.	32583	patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	32584	patients with hypertension	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	32584	patients with hypertension	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	32584	patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with Heart FailurepEF.	32584	patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QoL in patients with Heart FailurepEF is ineffective.	32587	patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QoL in patients with Heart FailurepEF is ineffective.	32587	patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nutritional supplements is not recommended for patients with Heart FailurepEF.	32588	patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Routine use of nutritional supplements is not recommended for patients with Heart FailurepEF.	32588	patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C0337422	Excision urachal sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C0191654	Excision pilonidal sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C3513226	Removal nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C3520151	Surgical endoscopy nose sinus with exploration frontal sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C0869682	Incision nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C0189160	Irrigation nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C3513194	Irrigation drainage sinus
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C3669066	Injection sinus tract
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	sinus rhythm	C3702146	Rhythm ECG leads
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	NYHA class II, III, or ambulatory class IV symptoms	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	NYHA class II, III, or ambulatory class IV symptoms	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	Cardiac resynchronization therapy is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32590	NYHA class II, III, or ambulatory class IV symptoms	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C0337422	Excision urachal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C0191654	Excision pilonidal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C3513226	Removal nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C3520151	Surgical endoscopy nose sinus with exploration frontal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C0869682	Incision nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C0189160	Irrigation nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C3513194	Irrigation drainage sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C3669066	Injection sinus tract
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	sinus rhythm	C3702146	Rhythm ECG leads
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	NYHA class III/ambulatory class IV symptoms on GDMT	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	NYHA class III/ambulatory class IV symptoms on GDMT	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35% , sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT.	32592	NYHA class III/ambulatory class IV symptoms on GDMT	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C0337422	Excision urachal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C0191654	Excision pilonidal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C3513226	Removal nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C3520151	Surgical endoscopy nose sinus with exploration frontal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C0869682	Incision nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C0189160	Irrigation nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C3513194	Irrigation drainage sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C3669066	Injection sinus tract
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	sinus rhythm	C3702146	Rhythm ECG leads
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients who have LVEF of ?35%, sinus rhythm, LBBB with a QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory class IV symptoms on GDMT.	32593	NYHA class II, III, or ambulatory class IV symptoms on GDMT	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	CRT can be useful for patients on GDMT who have LVEF of ?35% and are undergoing placement of a new or replacement device with anticipated requirement for significant (>40%) ventricular pacing.	32595	patients on GDMT	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C0337422	Excision urachal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C0191654	Excision pilonidal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C3513226	Removal nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C3520151	Surgical endoscopy nose sinus with exploration frontal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C0869682	Incision nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C0189160	Irrigation nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C3513194	Irrigation drainage sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C3669066	Injection sinus tract
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	sinus rhythm	C3702146	Rhythm ECG leads
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	and NYHA class III/ambulatory class IV on GDMT	C0497659	class finding
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	and NYHA class III/ambulatory class IV on GDMT	C0497660	class findings
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV on GDMT.	32597	and NYHA class III/ambulatory class IV on GDMT	C0497661	class class findings
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C0337422	Excision urachal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C0191654	Excision pilonidal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C3513226	Removal nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C3520151	Surgical endoscopy nose sinus with exploration frontal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C0869682	Incision nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C0189160	Irrigation nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C3513194	Irrigation drainage sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C3669066	Injection sinus tract
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?35%, sinus rhythm, a non-LBBB pattern with a QRS duration of ?150 ms, and NYHA class II symptoms on GDMT.	32598	sinus rhythm	C3702146	Rhythm ECG leads
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C0337422	Excision urachal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C0191654	Excision pilonidal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C3513226	Removal nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C3520151	Surgical endoscopy nose sinus with exploration frontal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C0869682	Incision nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C0189160	Irrigation nasal sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C3513194	Irrigation drainage sinus
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C3669066	Injection sinus tract
Heart Failure 2017 ACC/AHA/HFSA	CRT may be considered for patients who have LVEF of ?30%, ischemic etiology of Heart Failure, sinus rhythm, LBBB with a QRS duration of ?150 ms, and NYHA class I symptoms on GDMT.	32599	sinus rhythm	C3702146	Rhythm ECG leads
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	hospitalized patients	C1314211	Three patients served
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	hospitalized patients	C1314212	Four patients served
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	hospitalized patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	hospitalized patients	C1314213	Five patients served
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	hospitalized patients	C1314214	more patients served
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	who present with low blood pressure	C1144864	Family/couple with client present
Heart Failure 2017 ACC/AHA/HFSA	Short-term, continuous intravenous inotropic support may be reasonable in those hospitalized patients presenting with documented severe systolic dysfunction who present with low blood pressure and significantly depressed cardiac output to maintain systemic perfusion and preserve end-organ performance.	32605	who present with low blood pressure	C1314130	Blood pressure measured (CKD)(DM)
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C0973439	patient with mild systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C3526570	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C2065027	Family psychotherapy with patient present
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C1113679	patient safety
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C3526576	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C0497702	Aphakic patient
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C0973444	patient with severe systemic disease
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C3526564	Psychotherapy minutes with patient
Heart Failure 2017 ACC/AHA/HFSA	Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with Heart Failure.	32607	patient with HF	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	hospitalized patients	C1314211	Three patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	hospitalized patients	C1314212	Four patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	hospitalized patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	hospitalized patients	C1314213	Five patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	hospitalized patients	C1314214	more patients served
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C3516497	Volume reduction blood unit blood product
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C3516393	Blood count blood cell (RBC) automated
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C1609549	Volume reduction blood blood product (eg blood cells platelets) each unit
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C0005800	Blood Analysis
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C0005841	Blood Transfusion
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C0373984	Splitting blood blood products each unit
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C3516500	Splitting blood blood products
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C3516489	Blood typing blood cell antigens
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C0371802	Transfusion blood blood components
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C0373690	Osmolality blood
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C0373570	Blood catecholamines
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C1616290	Special acquisition blood blood products
Heart Failure 2017 ACC/AHA/HFSA	Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion, and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.	32608	low blood pressure	C1314130	Blood pressure measured (CKD)(DM)
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	carefully selected patients	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3865445	Insertion drainage device
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3512176	Application groin halo device (stabilization device groin)
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3512175	Application pelvic halo device (stabilization device pelvis)
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3512174	Application cranial halo device (stabilization device skull)
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3705624	Percutaneous placement breast localization device using stereotactic device
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3869420	Care Management Evaluation Management Services
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C2236411	anticoagulant management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C2066451	Evaluation management service
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C3527100	Wheelchair management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C0374911	case management services
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C0150318	Radiation therapy management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C0520256	Preoperative Management Only
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C0520255	Postoperative Management Only
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	device management	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0038897	Cardiovascular Surgical Procedures
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0520261	Surgical Team
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C3701854	Hysteroscopy surgical
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C3701638	Thoracoscopy surgical
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C4291714	Surgical Destruction
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C3520509	Surgical endoscopy with surgical tissue ablation reconstruction atrium
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0282493	Surgical Endoscopy
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0038900	Endocrine Surgical Procedures
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C3869420	Care Management Evaluation Management Services
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C2236411	anticoagulant management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C2066451	Evaluation management service
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C3527100	Wheelchair management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0374911	case management services
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0150318	Radiation therapy management
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0520256	Preoperative Management Only
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C0520255	Postoperative Management Only
Heart Failure 2017 ACC/AHA/HFSA	Evaluation for cardiac transplantation is indicated for carefully selected patients with stage D Heart Failure despite GDMT, device, and surgical management.	32612	surgical management	C1610129	Patient Management
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C3521208	Intravascular ultrasound during diagnostic evaluation
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C3513831	Ultrasound evaluation blood vessel during diagnosis treatment
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C0191235	Initial pericardiocentesis
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C1971424	Initial evaluation condition (HEP C)(EPI DSP)
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C3534876	initial evaluation condition (DSP)
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C3516661	Antibody evaluation
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C0846574	Psychiatric evaluation
Heart Failure 2017 ACC/AHA/HFSA	Common precipitating factors for acute Heart Failure should be considered during initial evaluation, as recognition of these conditions is critical to guide appropriate therapy.	32614	during initial evaluation	C2018131	Sperm evaluation
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity.	32618	Patients with HF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart Failure admitted with evidence of significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity.	32618	Patients with HF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	If patients are already receiving loop diuretic therapy, the initial intravenous dose should equal or exceed their chronic oral daily dose	32619	patients are receiving loop diuretic therapy	C3248300	Patient receiving inhibitor/ARB therapy beta-blocker therapy less than months patient receiving inhibitor/ARB therapy beta-blocker therapy (HF)
Heart Failure 2017 ACC/AHA/HFSA	The effect of Heart Failure treatment should be monitored with careful measurement of fluid intake and output, vital signs, body weight that is determined at the same time each day, and clinical signs and symptoms of systemic perfusion and congestion. Daily serum electrolytes, urea nitrogen, and creatinine concentrations should be measured during the use of intravenous diuretics or active titration of Heart Failure medications.	32620	patients with HF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	The effect of Heart Failure treatment should be monitored with careful measurement of fluid intake and output, vital signs, body weight that is determined at the same time each day, and clinical signs and symptoms of systemic perfusion and congestion. Daily serum electrolytes, urea nitrogen, and creatinine concentrations should be measured during the use of intravenous diuretics or active titration of Heart Failure medications.	32620	patients with HF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Ultrafiltration may be considered for patients with obvious volume overload to alleviate congestive symptoms and fluid weight.	32623	patients with obvious volume overload	C3865936	Whole blood volume determination with measurement plasma volume cell volume using radiopharmaceutical volume-dilution technique
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	32629	before hospital discharge,	C2362761	Inpatient hospital
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	32629	before hospital discharge,	C4291934	Campus-Outpatient Hospital
Heart Failure 2017 ACC/AHA/HFSA	Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients	32629	before hospital discharge,	C4291932	Campus-Outpatient Hospital
Heart Failure 2017 ACC/AHA/HFSA	Scheduling an early follow-up visit (within 7–14 days) and early telephone follow-up (within 3 days) of hospital discharge is reasonable.	32631	(within 3 days) of hospital discharge	C0374894	Hospital Discharge Services
Heart Failure 2017 ACC/AHA/HFSA	Scheduling an early follow-up visit (within 7–14 days) and early telephone follow-up (within 3 days) of hospital discharge is reasonable.	32631	(within 3 days) of hospital discharge	C3702191	Hospital discharge management
Heart Failure 2017 ACC/AHA/HFSA	Scheduling an early follow-up visit (within 7–14 days) and early telephone follow-up (within 3 days) of hospital discharge is reasonable.	32631	(within 3 days) of hospital discharge	C3517375	Hospital observation care discharge
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurerEF and hypertension should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg.	32636	Patients with HFrEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurerEF and hypertension should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg.	32636	Patients with HFrEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurepEF and persistent hypertension after management of volume overload should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg	32637	Patients with HFpEF	C1314210	patients served
Heart Failure 2017 ACC/AHA/HFSA	Patients with Heart FailurepEF and persistent hypertension after management of volume overload should be prescribed GDMT titrated to attain systolic blood pressure <130 mm Hg	32637	Patients with HFpEF	C1738525	Whole body integumentary photography monitoring high risk patients with dysplastic nevus syndrome history dysplastic nevi patients with personal familial history melanoma
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	In patients with cardiovascular disease	C3526717	Cardiovascular stress test with physician supervision with interpretation report
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	In patients with cardiovascular disease	C0973439	patient with mild systemic disease
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	In patients with cardiovascular disease	C0973444	patient with severe systemic disease
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C4291861	Repositioning neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C4291860	Removal neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C3704075	Sleep monitoring patient sleep
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C3517193	Sleep monitoring patient years older) sleep
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C0200101	Sleep electroencephalogram
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C4291859	Insertion replacement neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness	32639	obstructive sleep apnea	C4067660	Programming device evaluation implanted neurostimulator pulse generator system central sleep apnea during sleep study
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4291861	Repositioning neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4291860	Removal neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C3704075	Sleep monitoring patient sleep
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C3517193	Sleep monitoring patient years older) sleep
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C0200101	Sleep electroencephalogram
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067657	Repositioning neurostimulator system treatment central sleep apnea sensing lead only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067656	Repositioning neurostimulator system treatment central sleep apnea stimulation lead only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067653	Removal neurostimulator system treatment central sleep apnea sensing lead only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067654	Removal neurostimulator system treatment central sleep apnea stimulation lead only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067652	Removal neurostimulator system treatment central sleep apnea pulse generator only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4292059	Insertion replacement complete neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067649	Insertion replacement neurostimulator system treatment central sleep apnea sensing lead only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4291859	Insertion replacement neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067660	Programming device evaluation implanted neurostimulator pulse generator system central sleep apnea during sleep study
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4292062	Replacement pulse generator neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4292061	Insertion replacement pulse generator neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4292060	Insertion replacement stimulation lead neurostimulator system treatment central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067659	Programming device evaluation implanted neurostimulator pulse generator system central sleep apnea single session
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067658	Interrogation device evaluation implanted neurostimulator pulse generator system central sleep apnea
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067655	Removal replacement neurostimulator system treatment central sleep apnea pulse generator only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067651	Insertion replacement neurostimulator system treatment central sleep apnea pulse generator only
Heart Failure 2017 ACC/AHA/HFSA	In patients with NYHA class II–IV Heart FailurerEF and central sleep apnea, adaptive servo-ventilation causes harm	32640	central sleep apnea	C4067650	Insertion replacement neurostimulator system treatment central sleep apnea stimulation lead only
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C)	32641	with angina	C3248525	Angina absent (CAD)
Heart Failure 2017 ACC/AHA/HFSA	Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C)	32641	with angina	C3248257	Angina present (CAD)